



Article

# Searching Hit Potential Antimicrobials in Natural Compounds Space Against Biofilm Formation

Roberto Pestana-Nobles <sup>1</sup>†, Jorge A. Leyva-Rojas <sup>1</sup>† and Juvenal Yosa <sup>1</sup>†\*

<sup>1</sup> Universidad Simón Bolívar, Facultad de Ciencias Básicas y Biomédicas, Laboratorio de Simulación Molecular y Bioinformática, Barranquilla, 080002, Colombia.

\* Correspondence: juvenal.yosa@unisimonbolivar.edu.co

† These authors contributed equally to this work.

Version September 2, 2020 submitted to *Molecules*

**Abstract:** Biofilms are communities of microorganisms that can colonize biotic and abiotic surfaces playing a significant role in the persistence of bacterial infection and antibiotic resistance. About 65% and 80% of microbial and chronic infections are produced by biofilm formation. The increase in infections by multi-resistant bacteria draws attention to the discovery of new drugs based on natural inhibitory molecules. The inhibition of diguanylate cyclases (DGCs), the enzyme implicated in the synthesis of the second messenger, cyclic diguanylate (c-di-GMP), involved the biofilm formation, represents a potential method for preventing the biofilm development. It has been extensively studied using PleD protein as a model of DGC for *in silico* studies as virtual screening and as a model for *in vitro* studies in biofilms formation. In the present study 224205 molecules from natural products database, ZINC15 has been evaluated through molecular docking and molecular dynamic simulation, our result suggests *trans*-Aconitic acid (TAA) as a possible starting point for hit-to-lead methodologies to obtain new molecules capable of inhibiting the PleD protein and hence blocking the biofilm formation.

**Keywords:** Biofilms; virtual screening; molecular dynamics; natural products; binding energy; *trans*-Aconitic acid; hit-to-lead

## 1. Introduction

Biofilms are communities of microorganisms that can colonize surfaces, they have been found on both biotic and abiotic surfaces playing a significant role in the persistence of bacterial infection. The microorganisms are embedded in a self-produced extracellular matrix of extracellular polymeric substances (EPS) [1,2]. The biofilms formation provides advantages for the microorganisms. The change from free-living bacteria to biofilm involves the production of adhesins and extracellular matrix compound interconnecting the cells in the biofilms [3]. The extracellular matrix helps to support and connect the cell-to-cell interaction in the biofilms and plays an important purpose in several processes including cell attachment, cell-to-cell connecting, structural function, and antibiotic tolerance. This matrix producing by the bacteria is mainly composed of proteins, enzymes, polysaccharides, signalling molecules and extracellular DNA [4].

This microorganism assemblage provides a protected mode of growth with some resistance to antimicrobial and to killing by the host immune system. The biofilm development makes possible the surviving of the pathogen microorganisms in hostile environments and to disperse and colonize other niches also. [5].

In the medical field, the biofilm phenotype has been recognized as an active agent in the development of many infections, being the most common, those related to the use of medical devices[6]. The National Institutes of Health have reported that, among all microbial and chronic infections, 65%,




34 and 80%, respectively, are associated with biofilm formation [7]. The understanding of the molecular  
35 and physiological mechanisms of biofilm formation will bring a tool to inhibit its establishment.

36 The cyclic diguanylate (c-di-GMP) is an important second messenger involved in the biofilm  
37 organization [8]. This signalling molecule modulates bacterial growth phenotypes but not only limited  
38 to biofilm formation, virulence factor production, and motility. [8,9]. The synthesis of c-di-GMP  
39 depends on diguanylate cyclases (DGCs) which take two molecules of guanosine-5'-triphosphate (GTP)  
40 to obtain c-di-GMP in a two-step reaction. While, phosphodiesterases (PDEs) hydrolyse c-di-GMP  
41 to linear di-GMP [9,10]. The inhibition of DGCs as a strategy for preventing the biofilm formation  
42 represents a potential method, it has been extensively studied using PleD protein (EC: 2.7.7.65) as a  
43 model of DGC for *in silico* studies, using virtual screening and as a model for *in vitro* studies in biofilms  
44 formation [8–12].

45 The increase in infections by multi-resistant bacteria draws attention to the discovery of new drugs.  
46 Bioactive molecules are efficient natural compounds against living organisms, they are synthesized by  
47 microorganisms, plants and animals. These substances act as a chemical defence in various competitive  
48 environments [13]. An alternative for selecting DGC natural inhibitory-molecules is the search in the  
49 database of natural products, which could supply substances, especially small compounds, with good  
50 binding to the target enzyme.

51 Since the discovery of penicillin natural products plays an important role in the discovery and  
52 development of new drugs [14,15]. Between 1981 and 2014 were approved 43.6% of anti-infective  
53 drugs and 40.7% of anticancer agents where was based on a natural product or derivatives thereof [15],  
54 many natural products have become a template for drug design because of often present ligand-protein  
55 binding motifs [16]. Some natural products have shown antibacterial activity like the described by  
56 Nofianiet al [17] or Emiru et al [18].

57 In the present study, an evaluation of the of diguanylate cyclase, having as a model the PleD  
58 protein from *Caulobacter crescentus* against 224205 molecules from natural resources from the ZINC15  
59 database is carried out. Here, virtual screening VS, molecular dynamics (MD) simulations and binding  
60 free energy calculation adopting the Molecular Mechanics Poisson-Boltzmann Surface Area method  
61 (MM/PBSA) were used for the hit searching. A summary of the complete procedure is shown in  
62 Figure 1. This work aimed to propose potential hit substance from natural compounds database that  
63 can be optimized to generate a promising lead candidate compounds as a competitive ligand for the  
64 diguanylate cyclase proteins.



**Figure 1.** Summary of the procedure used for hit identification. An initial 20 ns of MD was performed with the PleD protein (inactive form) in complex with GTP molecule and  $Mg^{2+}$  ions, following the crystal structure of the active form 2V0N to coupling the GTP at the catalytic site. From equilibrated trajectory starting at 1.2 ns, an average structure was produced using chimera software [19]. A library of about 224205 natural products compounds was obtained from ZINC15 database. Bond orders, tautomeric forms, stereochemistry, hydrogen atoms and protonation states were assigned automatically by the ICM package with default parameters for each compound to prepare the ligands for docking. Ligands were docked using a VS scheme from ICM using the PleD protein average structure obtained in the above procedure. The GTP geometric space in the protein was used as a reference for the calculation of grid dimensions. 100 hits were obtained from VS procedure using the ICM energy scoring function for ranking it. From 100 hits, 35 with the best ICM energy score, were selected for 10 ns of MD simulations. For each molecule, MM/PBSA was computed using 200 frames from the last 2 ns of each MD. Finally, with the best complex (Ligand 4)-PleD, ranked from MM/PBSA binding free energy, a 110 ns of MD was done, also for GTP-PleD protein complex and PleD protein. From the above three trajectories, MM/PBSA was computed again at different windows starting from 20 ns until 60 ns, using for each window 200 frames.

## 65 2. Results and Discussion


66 The diguanylate cyclase PleD protein of *Caulobacter crescentus* belongs to response regulator family,  
 67 its activity is controlled by phosphorylation where two cognate kinases are involved; DivJ and PleC.  
 68 PleD is required for polar differentiation in the bacterial cell cycle. Bacterial cells without functional  
 69 PleD are hypermobile and fail to accomplish the swarmer-to-stalked cell transition [20–23]. PleD  
 70 protein contains an intrinsic nucleotide cyclase activity, which converts two molecules of GTP into  
 71 3',5'-cyclic diguanylic acid (c-di-GMP).[21]. c-di-GMP is a molecule of great interest which regulates  
 72 surface-adhesion properties and motility in bacteria [24,25]. In addition, c-di-GMP is involved in  
 73 bacterial biofilm formation and persistence[26]. Due to the fact that c-di-GMP is found exclusively in  
 74 bacteria, makes it a potential target for medicinal applications.

75 From the pseudo-active structure (PDB-ID: 2V0N) the mode of substrate binding as far as the  
 76 position of the terminal phosphates close to the P-loop, together with two  $Mg^{2+}$  ions, which are  
 77 coordinated by the phosphates and two invariant carboxylates (ASP327 and GLU370). Chain A from


78 an inactive structure (PDB-ID: 1W25), was chosen for MD and VS simulation, a GTP molecule and two  
79  $Mg^{2+}$  ions were added to the catalytic site of the protein, keeping the position of the substrate (GTP)  
80 mention above, from the pseudo-active structure. Also, ASP52 was phosphorylated, parameters for  
81 the phosphate group were obtained following the procedure mentioned elsewhere [27].

82 Molecular dynamics was done for the complex PleD-GTP for 20 ns. The monomer of PleD (chain  
83 A) was chosen and GTP molecule was added to the structure in the catalytic site, together with  $Mg^{2+}$   
84 ions and phosphorylation at ASP52. Charges and atom types, for each ligand, were assigned from the  
85 gaff force field.

86 The system converges at 1.2 ns of simulation (Figure S1 supplementary material). From 1.2 ns an  
87 average structure for the rest of the trajectory was computed for virtual screening (VS) simulation using  
88 Chimera package [19] Figure 2. First, molecular docking was done with the GTP molecule, obtained  
89 an ICM energy score of about -27.64 kcal/mol (Table S1 supplementary material). Virtual screening  
90 was done with natural compounds library from ZINC15, having as a reference the GTP molecule from  
91 the average structure. The coordinates of the ligands were extracted from the sdf file from ZINC15  
92 natural compounds library. Bond orders, tautomeric forms, stereochemistry, hydrogen atoms and  
93 protonation states were assigned automatically by the ICM package with default parameters [28].  
94 Atom types, charges and parameters were obtained from MMFF (Merck Molecular Force Field) force  
95 field for each ligand in the VS procedure. Geometry optimization was performed using the automatic  
96 converting procedure in ICM [28]). The ICM score for the best 100 hits molecules is summarized  
97 in table S1 supplementary material. These have ICM score energies ranging from -47.13 kcal/mol  
98 to -31.62 kcal/mol. As results from the VS procedure, the first 100 natural compounds have better  
99 ICM score energy than the GTP, Figure 3. The main idea of this work is to find a compound from  
100 natural product source, which can block the active site of the PleD protein, in that way, blocking the  
101 formation of the c-di-GMP. To do that, a more accurate calculation of the binding free energy was done.  
102 MM/PBSA was used in order to compute the binding free energies for the best 35 ICM energy score  
103 molecules from VS.



**Figure 2.** Average structure of PleD protein obtained from 20 ns of MD simulation. GTP, ASP52-phosphate moiety and  $Mg^{2+}$  ions are presented in the ball and stick representation.



**Figure 3.** Best poses for the first 100 hits ranked according to ICM energy score. In orange dot envelope representation of the space found in the average structure for GTP.


#### 104 2.1. Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA)

105 The best 35 ligands from the VS simulations were selected to perform a 10 ns of molecular  
 106 dynamics simulation. From this results, the best 6 molecules with the best binding free energy  
 107 MM/PBSA were studied. For the 35 ligands, the energy values were ranked between -121.39  
 108 (ZINC04501392) and -12.84 kcal/mol (ZINC15956889), the complete list is shown in the table S2  
 109 supplementary materials. On the other hand, the GTP molecule has a binding free energy of about  
 110 -178.09 kcal/mol. The difference in energy from VS and MM/PBSA calculation lies not only in the  
 111 method, but the parameter and charges used for this type of calculation (see methods).

112 The six ligands with the best binding free energy according to MM/PBSA calculations, are listed  
 113 in table 1 with the ZINC15 id. In Figure 4 a 2D structure representation for the GTP and molecules  
 114 are shown. Previous studies report antibacterial activity using one of these ligands or derivatives  
 115 of them, for example, the citrate can be used to functionalize and synthesize nanoparticles with  
 116 antibacterial activity [29,30]. In searching for new nematocidal factors from *Bacillus thuringiensis* against  
 117 the plant-parasitic nematode *Meloidogyne incognita*, a component identified as *trans*-Aconitic acid (TAA)  
 118 was found. The acid showed high nematocidal activity, suggesting that TAA is specifically synthesized  
 119 by the bacillus as a virulence factor, TAA acid has shown activity nematocide for *Bacillus thuringiensis*  
 120 bacterium [31].

**Table 1.** Show the ZINC15 id and the common name for the best six MM/PBSA binding free energy score compounds.

Zinc15 id	Name in this work	Common name
ZINC00895081	Ligand1	Citrate
ZINC03870145	Ligand2	Phosphoenolpyruvic acid
ZINC04028701	Ligand3	3-carboxy-2-(carboxymethyl)oxirane-2-carboxylate
ZINC04501392	Ligand4	<i>trans</i> -Aconitic acid
ZINC19336068	Ligand5	bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetic acid
ZINC27558828	Ligand6	2,3-Bis[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]oxysuccinic acid



**Figure 4.** 2D structure of the six ligands with the best MM/PBSA performance.

121 The MM/PBSA calculation brings the information of how strong is the binding between protein  
 122 and ligand, for this, the algorithm considers the binding free energy equal to the free energy of the  
 123 complex minus the sum of the free energy of the protein plus the free energy of the ligand, see equation  
 124 (1).

$$\Delta G = G_{\text{complex}} - (G_{\text{protein}} + G_{\text{ligand}}) \quad (1)$$

125 Each  $G$  component from equation (1) can be calculated as:

$$\Delta G = \langle E_{MM} \rangle - TS + \langle G_{\text{solvation}} \rangle \quad (2)$$

Where  $\langle E_{MM} \rangle$  is the average molecular mechanics potential energy in vacuum, T is the temperature, S is the entropy and  $\langle G_{solvation} \rangle$  is the free energy of solvation. The term  $\langle E_{MM} \rangle$  include energy of both bonded and nonbonded interactions,  $E_{bonded}$  and  $E_{nonbonded}$ . The  $E_{bonded}$  are consider of bond, angle, dihedral and improper interactions.  $E_{bonded}$  consider electrostatic ( $E_{elec}$ ) and van der Waals ( $E_{vdW}$ ) interactions, see equation (3).  $\langle G_{solvation} \rangle$  are included polar and non polar free energies, polar contribution is calculated using Poisson-Boltzmann equation and nonpolar contribution includes repulsive and attractive forces between solute and solvent generated by cavity,  $E_{cavity}$  formation and van der Waals interactions,  $E_{vdW}$ , see equation (4), for more information about how the equation works and how it is calculated consult the work of Kumari et al. [32], Baker et al. [33], Wissler et al. [34] and Konecny et al. [35].


$$\langle E_{MM} \rangle = E_{bonded} + E_{nonbonded} = E_{bonded} + E_{vdW} + E_{elec} \quad (3)$$

$$\langle G_{solvation} \rangle = G_{polar} + G_{nonpolar} = G_{polar} + E_{cavity} + E_{vdW} \quad (4)$$


A lower value of  $\Delta G$  means a better coupling between protein and ligand. The table 2 shows the values obtained for the 6 ligands with the best binding free energy. Results show that non of the molecules tested get the same or close binding free energy as GTP, the difference between GTP and ligands energies are; Ligand1 78 kcal/mol, Ligand2 74.77 kcal/mol, Ligand3 58.51 kcal/mol, Ligand4 56.76 kcal/mol, Ligand5 70.16 kcal/mol and Ligand6 77.11 kcal/mol, the biggest difference is presented by Ligand1 and the lowest difference is with Ligand4. In order to have a better insight of which residues contribute more to the  $\Delta G$  binding free energy, energy decomposition was performed (see methodology section for details), with this, the total  $\Delta G$  energy is presented as a contribution per residue, with this information we can classify residues into favourable and non-favourable interactions.

**Table 2.** Contribution of energies in the MM/PBSA calculation, all energy values are in kcal/mol.


Ligand	VDWAALS	EEL	EPB	ENPOLAR	DELTA G
Ligand1	2.92 ± 4.30	-867.68 ± 21.67	766.94 ± 18.20	-1.64 ± 0.06	-99.46 ± 5.67
Ligand2	19.03 ± 4.87	-736.68 ± 24.60	615.55 ± 21.83	-1.22 ± 0.06	-103.32 ± 4.81
Ligand3	8.72 ± 5.14	-776.77 ± 38.28	650.15 ± 35.30	-1.67 ± 0.06	-119.58 ± 7.11
Ligand4	7.86 ± 4.83	-807.77 ± 33.78	680.01 ± 29.12	-1.43 ± 0.09	-121.33 ± 9.13
Ligand5	-2.20 ± 5.73	-686.56 ± 28.76	583.50 ± 27.10	-2.67 ± 0.13	-107.93 ± 8.92
Ligand6	-20.27 ± 4.39	-533.33 ± 19.94	456.46 ± 16.33	-3.84 ± 0.11	-100.98 ± 7.20
GTP	-10.86 ± 6.45	-1287.03 ± 35.53	1123.46 ± 29.55	3.49 ± 0.17	-178.09 ± 10.82



**Figure 5.** Interaction per residue, from residue 300 to 457, all energies were calculated in kcal/mol. **(a)** Contribution of all residues on the MM/PBSA energy for GTP. **(b)** Zoom from residue 300 to 457 for the GTP, **(c)** Ligand1, **(d)** Ligand2. Residues with a contribution higher than 1 or lower than -1 are marked.



**Figure 6.** Interaction per residue from residue 300 to 457, all energies were calculated in kcal/mol. (a) Ligand3, (b) Ligand4, (c) Ligand5 and (d) from Ligand6. Residues with a contribution higher than 1 or lower than -1 are marked.



**Figure 7.** Contribution per residues around 3 Å from the ligand in the MM/PBSA calculation for each ligand and GTP, blue colour means more favourable interaction meanwhile red colour means non-favourable interaction, the ligand is highlighted in green.

145      Figure 5 only take into account the residues between 300 and 457, because as is shown in Figure  
 146 5a the first 300 residues do not show contribution to the binding free energy. For Figure 5 and  
 147 Figure 6 negative values are considered as favourable interaction, the interactions between two of the  
 148 three magnesium present in the protein play a role coordinating the carboxyl groups in all 6 ligands


149 including GTP which help to gain more stability. Taking the GTP as a reference, an interaction is  
 150 observed with ARG445, this is a highly favourable interaction which is not present in any of the 6  
 151 ligands evaluated, suggesting this residue as an important residue in the binding pocket which help to  
 152 reach a more stable conformational configuration. The ligands show common interactions with LYS331,  
 153 LYS441, PHE329 and PHE330 as favourable except for the Ligand2 presumably because this ligand  
 154 is the shortest one limiting its interaction with the protein. The result of positive energy suggest a  
 155 non-favourable interaction with the protein residues, all ligands show non-favourable interaction with  
 156 ASP326, ASP328, GLU369, ILE327 and GLU370, these four residues are common and have the higher  
 157 positive values among the ligands. All ligands except for Ligand4 and Ligand6 show non-favourable  
 158 interaction with ASP434. The non-favourable interaction for the GTP is mainly with ASP326 and  
 159 GLU369.

### 160 2.1.1. Root Mean Square Deviation (RMSD)

161 From the 10 ns molecular dynamic simulation used for the calculation of MM/PBSA, a RMSD  
 162 analysis was done. The RMSD was used to verify the protein stability during the entire simulation  
 163 [36], less deviation in these value means more stability in the protein. For these, the table 3 show the  
 164 average of the RMSD for the 6 ligands and the GTP. As the Figure 8 show the 6 ligands stabilize around  
 165 7 ns of simulation and GTP around 4 ns. These values were obtained using cpptraj tool [37] aligning to  
 166 the first frame of the production part of the simulation, the result suggests a stable configuration of the  
 167 protein with the ligands as we can see the same behaviour in the Figure 8, GTP shows less variation  
 168 compared to the rest of the ligands.

**Table 3.** The average RMSD for each Pled-ligand and Pled-GTP complexes, in angstroms with its standard deviation considering the entire production.

Ligand	RMSD	Difference between GTP and ligand
Ligand1	2.261 ± 0.365	0.284
Ligand2	2.189 ± 0.336	0.212
Ligand3	2.165 ± 0.411	0.188
Ligand4	2.480 ± 0.255	0.503
Ligand5	2.506 ± 0.350	0.529
Ligand6	2.305 ± 0.389	0.328
GTP	1.977 ± 0.289	0



**Figure 8.** RMSD calculation for the 10 ns of production for each ligand and GTP.

### 169 2.1.2. Hydrogen bonds (H-bonds)

170 Hydrogen bonds represent an important interaction between protein-ligand complexes and  
 171 the main reason for protein-ligand selectivity, this is why hydrogen bond analysis is often used to  
 172 describe affinity between protein and ligand [38]. Using hbond function in the cpptraj tool we analyze


173 the average amount of time at which hydrogen bond was present during the simulation, from this  
 174 information, it can be seen, which ones among all the residues, in the protein have more H-bond  
 175 formation with the ligands. For these, the H-bond analysis for each ligand (including GTP) was done  
 176 using a threshold of 3 Å around the ligands during all the production taking in account frame by  
 177 frame.

**Table 4.** Residues involved in the H-bond formation with the percentage of how long this bond was present during the entire 10 ns of simulation.

Ligand	Residues involve in the h-bond formation with the major contribution
Ligand1	LYS441(54.20%), LYS331(35.88%), PHE330(7.11%), PHE329(2.80%)
Ligand2	LYS441(85.28%), PHE329(9.37%), PHE330 (4.97%)
Ligand3	LYS441(38.70%), PHE329(24.17%), PHE330(19.74%), LYS331(17.39%)
Ligand4	LYS441(52.68%), LYS331(24.05%), PHE330(19.28%), PHE329(3.99%)
Ligand5	LYS441(54.31%), PHE330(35.45%), LYS331(9.31%)
Ligand6	LYS441(36.13%), LYS331(23.48%), PHE330(17.81%), ASN334(17.03%), LYS332(4.77%)
GTP	ARG445(39.05%), LYS331(34.63%), LYS441(17.35%), PHE330(8.12%)

178 Among all ligands evaluated, the LYS441 is the more important residue in the H-bond formation.  
 179 In some cases being present in more than the 80% of the production (Ligand2). Residues PHE331,  
 180 PHE330 and LYS331 were also present as relevant. For the GTP the residue with more interactions was  
 181 the ARG445, this also is seen the MM/PBSA decomposition results.

182 A second analysis was performed to observe the behaviour of the best ligand obtained in the  
 183 MM/PBSA calculation, which is Ligand4. For this, 100 ns of molecular dynamics with the same  
 184 condition of the previous 10 ns were done. The starting point for this new simulation was the ending  
 185 of the previous one giving a total of 110 ns of simulation. In this second analysis, the PleD-protein  
 186 without any ligand, to serve as a reference, the complex PleD-GTP and the complex PleD-Ligand4,  
 187 were taken for simulations. MM/PBSA calculations were done, using different time windows, 20,  
 188 30, 40, 50 and 60 ns of the molecular simulation were consider, in each window, the same amount of  
 189 snapshots (200) were taken.

190 2.2. *Trans*-Aconitic Acid (Ligand4)

**Figure 9.** Analysis results from the second production of 110 ns, (a) RMSD in angstrom, (b) RMSF in angstrom, (c) Radius of gyration (Rg) in angstrom, (d) Hydrogen bonds for GTP and (e) Hydrogen bonds for Ligand4.

### 191 2.2.1. Root Mean Square Deviation (RMSD)

192 The RMSD show high stability in the three cases (PleD, GTP and Ligand4), 9.a, the average  
 193 value with it standard deviation for the PleD-protein  $2.75 \pm 0.31$ , PleD-GTP complex  $2.57 \pm 0.28$  and  
 194 PleD-Ligand4 complex  $3.20 \pm 0.45$ . The PleD-protein present a higher value than PleD-GTP meaning  
 195 GTP help the protein itself to reach a more stable configuration. The PleD-Ligand4 is the one who  
 196 presents more variation although has high stability during the dynamic as is represented in the low  
 197 standard deviation.

### 198 2.2.2. Root Mean Square Fluctuation (RMSF)

199 For the RMSF the same approach as the MM/PBSA was made, the graph just take into account  
 200 residues 300-457 which are the residues were the interaction are establish, Figure 9b, the same  
 201 fluctuation is observed in the protein structure for the three cases, specifically in the PleD-GTP,  
 202 a major variation in residues 450-455 is present, the average variation with the standard deviation is  
 203  $1.65 \pm 0.63$  for the PleD-protein,  $1.53 \pm 0.87$  for PleD-GTP complex and  $1.53 \pm 0.62$  for PleD-Ligand4  
 204 complex. The RMSF analysis agrees with the RMSD showing the PleD by itself present lower stability  
 205 compared to a binding PleD with GTP.

### 206 2.2.3. Radius of gyration

207 The Radius of gyration (Rg) can give an idea of the compactness of a protein structure [39],  
 208 the Figure 9c suggest structural stability in the 3 systems here considered however the complex  
 209 PleD-Ligand4 less Rg value in comparison of the other two structures. The average value with the  
 210 standard deviation for the three systems are  $25.48 \pm 0.27$  for PleD-protein,  $25.36 \pm 0.26$  PleD-GTP and  
 211  $24.1 \pm 0.17$  PleD-Ligand4.

### 212 2.2.4. Hydrogen bond (H-bond)

213 The H-bond analysis results for the 110 ns production (5) show differences compared to the  
 214 results from the table 4, for the GTP is observed the same tendency as the previous result, where the  
 215 residue ARG445 is the one which is present for more time during the simulation, in this case, the  
 216 order is maintained, the LYS331, LYS441 and PHE330 residues come after the ARG445. In the case of  
 217 the Ligand4 there are different order, in this case, the residue PHE330 is the one with more presence  
 218 followed by LYS331 and LYS441.

**Table 5.** Residues involved in the H-bond formation with the percentage of how long this bond was presented during the entire simulation for the 110 ns of simulation.


Ligand	Residues involve in the h-bond formation with the major contribution
PleD-Ligand4	PHE330(9.7%) ,LYS331(6.01%), LYS441(5.69%)
PleD-GTP	ARG445(41.44%), LYS331(15.14%), LYS441(12.07%), PHE330(11.95%)

219 The H-bond formation shows that, during the production, the GTP is making even nine H-bonds  
 220 while the Ligand4 just make only four as is shown in Figure 9d and 9e. The GTP present the double of  
 221 H-bond compared to the Ligand4, this is due to the phosphate group (the GTP has 3 of them) which  
 222 provide more possible points to establish H-bonds thanks to the hydroxyl group (10 in the whole  
 223 structure), instead of the Ligand4 which only have 6 hydroxyl group.

### 224 2.2.5. Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA)

225 The MM/PBSA values here presented are averages of the windows establish in this step, the values  
 226 are (with the standard deviation);  $-169.93 \pm 4.03$  for PleD-GTP and  $-98.79 \pm 0.43$  for PleD-Ligand4. In  
 227 the Figure 10 are represented the average values of the residues from the different windows (20, 30,  
 228 40, 50 and 60), compared to the previous results (Figure 5) for the GTP, here can be seen a similarity,

229 which indicates the same tendency for the residues like ASP326, ASP328 and GLU369 which have  
 230 non-favourable interaction while ARG445, LYS441, LYS331, PHE330 and PHE329 have the major  
 231 favourable contribution to the interaction with the GTP, suggesting the importance of these residues in  
 232 the binding pocket. In the case of Ligand4, the residues showed the same tendency as in the simulation  
 233 of 10 ns, ASP326, ILE327, ASP328, GLU369 and GLU370 residues, show non-favourable interaction  
 234 while residues PHE329, LYS331 and LYS441 show favourable interaction. In both cases, the magnesium  
 235 atoms present an important contribution to the binding free energy.



**Figure 10.** MM/PBSA Average ligand binding free energies for the 110 ns of simulation. Here, the residues 300 to 457 were taken into account. (a) GTP and (b) Ligand4.

236 The low standard deviation for the reported result at different windows is interpreted as high  
 237 stability of the complexes, comparing the two MM/PBSA result (first and second analysis) some  
 238 variation in energy are presented and the emergence or disappearance of new residues as GLU370 or  
 239 ASP343 for GTP, and LYS332 for the Ligand4, is due to better conformational sampling obtained with  
 240 more simulation time (110 ns). The result of the MM/PBSA with a short dynamic gives us an idea of  
 241 the overall interaction and also of possible favourable or non-favourable ones.

242 For the GTP results, where the major contribution for the MM/PBSA binding free energy is the  
 243 H-bond formation from ARG445, suggest this residue as a key one for the ligand-protein interaction.  
 244 The absence of this interaction with the rest of the ligands can indicate a lower binding free energy in  
 245 comparison with the GTP. Both MM/PBSA results, the one obtained by 10 ns and the average from  
 246 the five windows, showed that the Ligand4 has good stability, suggesting this molecule as a possible  
 247 template for design new ligand who can surpass the GTP binding free energy and effectively inhibit  
 248 the PleD protein.

249 In this research the binding free energy was calculated by MM/PBSA method and was used to  
 250 define a possible compound capable of inhibiting the PleD protein and hence blocking the formation  
 251 of biofilms, the *trans*-aconitic acid performed the best among the 224205 ligands here studied. This  
 252 compounds is found in plants like *Zea mays*, *Triticum aestivum*, *Avena sativa*, *Brachiaria plantaginea*  
 253 and *Saccharum officinarum* [40]. Methodologies of extraction are described by Schnitzler et al. [41]  
 254 and Kanitkar et al. [42]. In our results *trans*-aconitic acid does not surpass GTP binding free energy,  
 255 however it does not mean that can not be used, our results suggest good interaction with the PleD  
 256 protein, further optimization can be made to improve the results, strategies like Fragment-Based Drug

257 Discovery (FBDD) [43] or Fragment Molecular Orbital (FMO) [44,45] can be use to optimized the hit to  
258 become an effective lead.

### 259 3. Materials and Methods

#### 260 3.1. Data collection

261 To search for antimicrobial agents from natural compounds, the ZINC15 [46] database was  
262 chosen. ZINC15 is a database with public access established to allow ready access to compounds for  
263 virtual screening. Molecules were downloaded in SDF format. ZINC 15 has a natural product-related  
264 compounds database of about 224205. All records from naturals products were download and stores  
265 in a single file.

#### 266 3.2. Virtual screening (VS)

267 Structure-based virtual screening applying docking simulations was performed using ICM  
268 software package [28,47–54]. Virtual Ligand Screening (VLS) in ICM was performed by docking  
269 the database downloaded from ZINC15 against PleD protein structure obtained from protein data  
270 bank PDB (PDB:ID 1W25) followed by an evaluation of the docked conformation with a binding-score  
271 function. The search space encompassed the catalytic domain, the DGC (GGDEF) domain consists of a  
272 five-stranded central  $\beta$ -sheet surrounded by  $\alpha$  helices (Figure 2). Water molecules and ligands had  
273 been removed from the original crystal structure. Phosphoryl analog  $\text{BeF}^{-3}$  attached to ASP52, was  
274 changed by phosphate group which was parameterized using the same procedure as was mention  
275 elsewhere [27]. A grid for space search was set up using as a reference the GTP $\alpha$ S and  $\text{Mg}^{2+}$  from  
276 2V0N crystal structure, with the following dimensions in Å: centre (x, y, z) = (52.14.6, 76.2), dimensions  
277 (x, y, z) = (21.2, 17.9, 17.9). The docking simulation was then run at exhaustiveness of 5 and set to only  
278 output the lowest energy pose.

#### 279 3.3. Ligand binding free energy calculations

280 For the ligands, no geometry optimization was applied because we kept the orientation obtained  
281 from the docking results. Charge for ligands were calculated with *ab initio* methods using B3LYP and  
282 6-31G as basis set in GAUSSIAN09 software [55]. With the output file from gaussian09, charges and  
283 topology file (prepi and frmod AMBER files respectively) were prepared using antechamber and  
284 parmchk2 from Ambertools18 [56]. Although antechamber generates a file with the charge information  
285 of ligands these charges were changes for the ones calculated with gaussian.

#### 286 3.4. System Preparation

287 The system consists of the protein-ligand complex embedded in a rectangular box with waters  
288 and ions, LEaP module of Amber was used for the preparation of all systems [56]. Initially, the  
289 mbondi2 parameter for PBRadii were set [57]. The ff14SB force field was used for the protein which is  
290 an improvement of ff99SB [58]. 35 ligands with the best ICM energy score were chosen. The GAFF  
291 force field was used for the ligands[59], all the system were embedded in a box of size 100, 79, 109 Å  
292 (approximately) for X, Y, Z respectively, we use TIP3P water type molecules [60,61] and  $\text{Na}^+$  ions were  
293 add to neutralize the charge.

#### 294 3.5. Molecular Dynamics (MD)

295 For all systems, first, a minimization of only waters molecules was done, for this, we restrain  
296 all the solute (protein and ligand) with a force of 100 kcal/mol-Å<sup>2</sup>, in this minimization we establish  
297 the maxcyc and the ncyc to 50000 and 1500 respectively, the ntc was 1 (the shake was off) this is  
298 recommended to do it during the minimization [56], constant volume was established. Then a

299 minimization of the entire system using this time maxcyc=100000 and ncyc=1000, again constant  
300 volume was done.

301 After energy minimization the system was gradually heated until 300 K for 50 ps, in this part the  
302 solute was restrained with a force of 2.0 kcal/mol-Å<sup>2</sup>, for the last step the system was equilibrated for  
303 5 nanoseconds (ns), we establish ntt=3, ntp=1, ntc=2 and ntf=2, with constant pressure. Finally, for the  
304 first analysis, we perform the production for 10 ns in NPT ensemble.

305 The second analysis of PleD protein, PleD-GTP and PleD-Ligand4 complexes, a 100 ns more were  
306 simulated. For the PleD-GTP and PleD-Ligand4, the 100 ns production start at the end of the previous  
307 10 ns, using the same conditions as the 10 ns production.

### 308 3.6. Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) Calculation

309 The binding free energy was calculated using the MM/PBSA script from AMBER package [62],  
310 in the first analysis a total of 200 snapshots were taken for the MM/PBSA analysis, these snapshots  
311 are equal to the last 2 ns of simulation, Su et al suggest that working with data of MD trajectories  
312 longer than 2 ns decreases the accuracy of the prediction [57]. The parameters igb = 2, inp = 1 and  
313 radiopt = 0 were used, the igb parameter is chosen depending on the mbondi parameters following the  
314 amber manual indications, the inp uses the solvent-accessible-surface area to correlate total nonpolar  
315 solvation free energy and radiopt indicating to use the default atomic radius of the input file [56]. In  
316 the calculation of MM/PBSA binding free energy entropy was not considerate, this due to the high  
317 computational cost of it and this contribution just improve the result slightly or even can decrease the  
318 effectiveness of the MM/PBSA method [63–65]. For the decomposition per residue of the MM/PBSA  
319 result, the &decomp general option was established with idecomp=1 in the same input file.

320 In the second analysis, we take the last 20, 30, 40, 50, 60 ns of production and 200 snapshots, with  
321 the same condition as the first MM/PBSA calculation.

### 322 3.7. RMSD, RMSF, Radius of gyration and H-bond

323 The RMSD (Root Mean Square Deviation), the RMSF (Root Mean Square Fluctuation), the radius  
324 of gyration (Rg) and H-bond (hydrogen bond formation) were calculated with cpptraj tool [37], we use  
325 the entire production to make this analysis and the first frame was taken as reference for alignment in  
326 the RMSD and RMSF analysis.

## 327 4. Conclusions

328 Computational methods, using virtual screening, play a significant role in drug discovery. The  
329 identification of the drug interaction with the target macromolecule can help to clarify the potential  
330 molecule's action mechanisms.

331 In our computational study, the binding free energy between PleD protein and ligands was  
332 calculated through MM/PBSA to rank the best molecules obtained from virtual screening of naturals  
333 products from ZINC15 database, we identify ARG445 as a key residue in the binding pocket, residues  
334 LYS441, LYS331, PHE 330 and PHE329 present favourable interaction and GLU369 present a common  
335 non-favourable interaction among the ligands here studied. Our results suggest *trans*-aconitic acid as a  
336 possible starting point for hit-to-lead methodologies.

337 **Supplementary Materials:** The following are available online at <http://www.mdpi.com/1420-3049/xx/1/5/s1>,  
338 Figure S1: title, Table S1: title, Video S1: title.

339 **Author Contributions:** Conceptualization, R.P.N, J.A.L.R and J.Y.; methodology, R.P.N and J.Y.; software, R.P.N  
340 and J.Y.; formal analysis, R.P.N and J.Y.; writing–original draft preparation, R.P.N.; writing–review and editing,  
341 R.P.N, J.A.L.R and J.Y.; visualization, R.P.N.; supervision, J.A.L.R and J.Y.;

342 **Funding:** This work was supported by "Convocatoria del Fondo de Ciencia, Tecnología e Innovación del Sistema  
343 General de Regalías para la conformación de una lista de proyectos elegibles para ser viabilizados, priorizados y  
344 aprobados por el OCAD en el marco del Programa de Becas de Excelencia Doctoral del Bicentenario 2019" which  
345 make possible the PhD studies of Roberto Pestana-Nobles.

346 **Acknowledgments:** This work was supported by "Convocatoria del Fondo de Ciencia, Tecnología e Innovación  
 347 del Sistema General de Regalías para la conformación de una lista de proyectos elegibles para ser viabilizados,  
 348 priorizados y aprobados por el OCAD en el marco del Programa de Becas de Excelencia Doctoral del Bicentenario  
 349 2019" which make possible the PhD studies of Roberto Pestana-Nobles.

350 **Conflicts of Interest:** The authors declare no conflict of interest.

### 351 Abbreviations

352 The following abbreviations are used in this manuscript:

353	EPS	Extracellular polymeric substances
	c-di-GMP	Cyclic diguanylate
	DGC	Diguanylate cyclases
	PDEs	Phosphodiesterases
	GTP	Guanosine-5'-triphosphate
354	TTA	<i>trans</i> -aconitic acid
	VS	Virtual screening
	MD	molecular dynamics
	MM/PBSA	Molecular Mechanics Poisson-Boltzmann Surface Area
	MMFF	Merck Molecular Force Field

### 355 References

- 356 1. Flemming, H.C.; Wingender, J.; Szewzyk, U.; Steinberg, P.; Rice, S.A.; Kjelleberg, S. Biofilms: an emergent  
 357 form of bacterial life. *Nature Reviews Microbiology* **2016**, *14*, 563–575. doi:10.1038/nrmicro.2016.94.
- 358 2. Yin, W.; Wang, Y.; Liu, L.; He, J. Biofilms: The Microbial "Protective Clothing" in Extreme Environments.  
 359 *International journal of molecular sciences* **2019**, *20*, 3423. doi:10.3390/ijms20143423.
- 360 3. Tolker-Nielsen, T. Biofilm Development. *Microbiology Spectrum* **2015**, *3*.  
 361 doi:10.1128/microbiolspec.MB-0001-2014.
- 362 4. Nadell, C.D.; Drescher, K.; Foster, K.R. Spatial structure, cooperation and competition in biofilms. *Nature*  
 363 *Reviews Microbiology* **2016**, *14*, 589–600. doi:10.1038/nrmicro.2016.84.
- 364 5. Del Pozo, J.L. Biofilm-related disease. *Expert Review of Anti-Infective Therapy* **2018**, *16*, 51–65.  
 365 doi:10.1080/14787210.2018.1417036.
- 366 6. Fleming, D.; Rumbaugh, K.P. Approaches to Dispersing Medical Biofilms. *Microorganisms* **2017**, *5*.  
 367 doi:10.3390/microorganisms5020015.
- 368 7. Jamal, M.; Ahmad, W.; Andleeb, S.; Jalil, F.; Imran, M.; Nawaz, M.A.; Hussain, T.; Ali, M.; Rafiq, M.; Kamil,  
 369 M.A. Bacterial biofilm and associated infections. *Journal of the Chinese Medical Association* **2018**, *81*, 7–11.  
 370 doi:10.1016/j.jcma.2017.07.012.
- 371 8. Fernicola, S.; Paiardini, A.; Giardina, G.; Rampioni, G.; Leoni, L.; Cutruzzola, F.; Rinaldo, S.  
 372 In Silico Discovery and In Vitro Validation of Catechol-Containing Sulfonohydrazide Compounds  
 373 as Potent Inhibitors of the Diguanylate Cyclase PleD. *Journal of Bacteriology* **2016**, *198*, 147–156.  
 374 doi:10.1128/JB.00742-15.
- 375 9. Cai, Y.M.; Hutchin, A.; Craddock, J.; Walsh, M.A.; Webb, J.S.; Tews, I. Differential impact on motility and  
 376 biofilm dispersal of closely related phosphodiesterases in *Pseudomonas aeruginosa*. *Scientific reports* **2020**,  
 377 *10*, 6232–6232. doi:10.1038/s41598-020-63008-5.
- 378 10. Römling, U.; Galperin, M.Y.; Gomelsky, M. Cyclic di-GMP: the First 25 Years of a Universal Bacterial  
 379 Second Messenger. *Microbiology and Molecular Biology Reviews* **2013**, *77*, 1–52. doi:10.1128/MMBR.00043-12.
- 380 11. Feirer, N.; Kim, D.; Xu, J.; Fernandez, N.; Waters, C.M.; Fuqua, C. The *Agrobacterium tumefaciens*  
 381 CheY-like protein ClaR regulates biofilm formation. *Microbiology (Reading, England)* **2017**, *163*, 1680–1691.  
 382 doi:10.1099/mic.0.000558.
- 383 12. Alviz-Gazitua, P.; Fuentes-Alburquenque, S.; Rojas, L.A.; Turner, R.J.; Guiliani, N.; Seeger, M. The Response  
 384 of *Cupriavidus metallidurans* CH34 to Cadmium Involves Inhibition of the Initiation of Biofilm Formation,  
 385 Decrease in Intracellular c-di-GMP Levels, and a Novel Metal Regulated Phosphodiesterase. *Frontiers in*  
 386 *Microbiology* **2019**, *10*, 1499. doi:10.3389/fmicb.2019.01499.

- 387 13. Lage, O.M.; Ramos, M.C.; Calisto, R.; Almeida, E.; Vasconcelos, V.; Vicente, F. Current screening  
388 methodologies in drug discovery for selected human diseases. *Marine Drugs* **2018**, *16*, 1–31.  
389 doi:10.3390/md16080279.
- 390 14. Rossiter, S.E.; Fletcher, M.H.; Wuest, W.M. Natural Products as Platforms to Overcome Antibiotic Resistance.  
391 *Chemical Reviews* **2017**, *117*, 12415–12474. doi:10.1021/acs.chemrev.7b00283.
- 392 15. Herrmann, J.; Fayad, A.A.; Müller, R. Natural products from myxobacteria: Novel metabolites and  
393 bioactivities. *Natural Product Reports* **2017**, *34*, 135–160. doi:10.1039/c6np00106h.
- 394 16. Rodrigues, T.; Reker, D.; Schneider, P.; Schneider, G. Counting on natural products for drug design. *Nature*  
395 *Chemistry* **2016**, *8*, 531–541. doi:10.1038/nchem.2479.
- 396 17. Nofiani, R.; Weisberg, A.J.; Tsunoda, T.; Panjaitan, R.G.P.; Brilliantoro, R.; Chang, J.H.; Philmus, B.;  
397 Mahmud, T. Antibacterial Potential of Secondary Metabolites from Indonesian Marine Bacterial Symbionts.  
398 *International Journal of Microbiology* **2020**, *2020*, 8898631. doi:10.1155/2020/8898631.
- 399 18. Emiru, Y.K.; Siraj, E.A.; Teklehaimanot, T.T.; Amare, G.G. Antibacterial Potential of *Aloe weloensis*  
400 (Aloeacea) Leaf Latex against Gram-Positive and Gram-Negative Bacteria Strains. *International Journal of*  
401 *Microbiology* **2019**, *2019*, 5328238. doi:10.1155/2019/5328238.
- 402 19. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF  
403 Chimera—A visualization system for exploratory research and analysis. *Journal of Computational Chemistry*  
404 **2004**, *25*, 1605–1612. doi:10.1002/jcc.20084.
- 405 20. Burton, G.J.; Hecht, G.B.; Newton, A. Roles of the histidine protein kinase pleC in *Caulobacter crescentus*  
406 motility and chemotaxis. *Journal Of Bacteriology* **1997**, *179*, 5849–5853. doi:10.1128/jb.179.18.5849-5853.1997.
- 407 21. Paul, R.; Weiser, S.; Amiot, N.C.; Chan, C.; Schirmer, T.; Giese, B.; Jenal, U. Cell cycle-dependent dynamic  
408 localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. *Genes &*  
409 *Development* **2004**, *18*, 715–727. doi:10.1101/gad.289504.
- 410 22. Aldridge, P.; Paul, R.; Goymier, P.; Rainey, P.; Jenal, U. Role of the GGDEF regulator PleD  
411 in polar development of *Caulobacter crescentus*. *Molecular Microbiology* **2003**, *47*, 1695–1708.  
412 doi:10.1046/j.1365-2958.2003.03401.x.
- 413 23. Aldridge, P.; Jenal, U. Cell cycle-dependent degradation of a flagellar motor component  
414 requires a novel-type response regulator. *Molecular Microbiology* **1999**, *32*, 379–391.  
415 doi:10.1046/j.1365-2958.1999.01358.x.
- 416 24. Jenal, U. Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved  
417 in modulating cell surface structures in bacteria? *Current Opinion in Microbiology* **2004**, *7*, 185–191.  
418 doi:10.1016/j.mib.2004.02.007.
- 419 25. Jenal, U.; Malone, J. Mechanisms of cyclic-di-GMP signaling in bacteria. *Annual Review of Genetics* **2006**,  
420 *40*, 385–407. doi:10.1146/annurev.genet.40.110405.090423.
- 421 26. Tamayo, R.; Pratt, J.T.; Camilli, A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis.  
422 *Annual Review of Microbiology* **2007**, *61*, 131–48. doi:10.1146/annurev.micro.61.080706.093426.
- 423 27. Yosa Reyes, J.; Nagy, T.; Meuwly, M. Competitive reaction pathways in vibrationally induced  
424 photodissociation of H<sub>2</sub>SO<sub>4</sub>. *Phys. Chem. Chem. Phys.* **2014**, *16*, 18533–18544. doi:10.1039/C4CP01832J.
- 425 28. Neves, M.A.C.; Totrov, M.; Abagyan, R. Docking and scoring with ICM: the benchmarking  
426 results and strategies for improvement. *Journal of computer-aided molecular design* **2012**, *26*, 675–686.  
427 doi:10.1007/s10822-012-9547-0.
- 428 29. Khatoon, U.T.; Nageswara Rao, G.V.S.; Mohan, K.M.; Ramanaviciene, A.; Ramanavicius, A. Antibacterial  
429 and antifungal activity of silver nanospheres synthesized by tri-sodium citrate assisted chemical approach.  
430 *Vacuum* **2017**, *146*, 259–265. doi:10.1016/j.vacuum.2017.10.003.
- 431 30. Choudhury, R.; Majumdar, M.; Biswas, P.; Khan, S.; Misra, T.K. Kinetic study of functionalization of citrate  
432 stabilized silver nanoparticles with catechol and its anti-biofilm activity. *Nano-Structures & Nano-Objects*  
433 **2019**, *19*, 100326. doi:10.1016/j.nanoso.2019.100326.
- 434 31. Du, C.; Cao, S.; Shi, X.; Nie, X.; Zheng, J.; Deng, Y.; Ruan, L.; Peng, D.; Sun, M. Genetic and Biochemical  
435 Characterization of a Gene Operon for trans-Aconitic Acid, a Novel Nematicide from *Bacillus thuringiensis*.  
436 *Journal of Biological Chemistry* **2017**, *292*, 3517–3530. doi:10.1074/jbc.M116.762666.
- 437 32. Kumari, R.; Kumar, R.; Lynn, A. g\_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA  
438 Calculations. *Journal of Chemical Information and Modeling* **2014**, *54*, 1951–1962. doi:10.1021/ci500020m.

- 439 33. Baker, N.A.; Sept, D.; Holst, M.J.; McCammon, J.A. The adaptive multilevel finite element solution of the  
440 Poisson-Boltzmann equation on massively parallel computers. *IBM Journal of Research and Development*  
441 **2001**, *45*, 427–438. doi:10.1147/rd.453.0427.
- 442 34. Weiser, J.; Shenkin, P.S.; Still, W.C. Approximate atomic surfaces from linear combinations  
443 of pairwise overlaps (LCPO). *Journal of Computational Chemistry* **1999**, *20*, 217–230.  
444 doi:10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A.
- 445 35. Konecny, R.B.; McCammon, N.A.; Andrew, J. iAPBS: a programming interface to the adaptive  
446 Poisson-Boltzmann solver. *Comput. Sci. Disc.*, **2012**, *5*. doi:10.1088/1749-4699/5/1/015005.
- 447 36. Sargsyan, K.; Grauffel, C.; Lim, C. How Molecular Size Impacts RMSD Applications in Molecular Dynamics  
448 Simulations. *Journal of Chemical Theory and Computation* **2017**, *13*, 1518–1524. doi:10.1021/acs.jctc.7b00028.
- 449 37. Roe, D.R.; Cheatham, T.E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of  
450 Molecular Dynamics Trajectory Data. *Journal of Chemical Theory and Computation* **2013**, *9*, 3084–3095.  
451 doi:10.1021/ct400341p.
- 452 38. Nittinger, E.; Inhester, T.; Bietz, S.; Meyder, A.; Schomburg, K.T.; Lange, G.; Klein, R.; Rarey, M. Large-Scale  
453 Analysis of Hydrogen Bond Interaction Patterns in Protein–Ligand Interfaces. *Journal of Medicinal Chemistry*  
454 **2017**, *60*, 4245–4257. doi:10.1021/acs.jmedchem.7b00101.
- 455 39. Lobanov, M.Y.; Bogatyreva, N.S.; Galzitskaya, O.V. Radius of gyration as an indicator of protein structure  
456 compactness. *Molecular Biology* **2008**, *42*, 623–628. doi:10.1134/S0026893308040195.
- 457 40. Bortolo, T.d.S.C.; Marchiosi, R.; Viganó, J.; Siqueira-Soares, R.d.C.; Ferro, A.P.; Barreto, G.E.; Bido, G.d.S.;  
458 Abrahão, J.; dos Santos, W.D.; Ferrarese-Filho, O. Trans-aconitic acid inhibits the growth and photosynthesis  
459 of *Glycine max*. *Plant Physiology and Biochemistry* **2018**, *132*, 490–496. doi:10.1016/j.plaphy.2018.09.036.
- 460 41. Schnitzler, M.; Petereit, F.; Nahrstedt, A. Trans-Aconitic acid, glucosylflavones and  
461 hydroxycinnamoyltartaric acids from the leaves of *Echinodorus grandiflorus* ssp. *aureus*,  
462 a Brazilian medicinal plant. *Revista Brasileira de Farmacognosia* **2007**, *17*, 149–154.  
463 doi:10.1590/S0102-695X2007000200002.
- 464 42. Kanitkar, A.; Aita, G.; Madsen, L. The recovery of polymerization grade aconitic acid from sugarcane  
465 molasses. *Journal of Chemical Technology & Biotechnology* **2013**, *88*, 2188–2192. doi:10.1002/jctb.4084.
- 466 43. De Souza Neto, L.R.; Moreira-Filho, J.T.; Neves, B.J.; Maidana, R.L.B.R.; Guimarães, A.C.R.; Furnham,  
467 N.; Andrade, C.H.; Silva Jr., F.P. In silico Strategies to Support Fragment-to-Lead Optimization in Drug  
468 Discovery. *Frontiers in chemistry* **2020**, *8*, 93–93. doi:10.3389/fchem.2020.00093.
- 469 44. Kitaura, K.; Ikeo, E.; Asada, T.; Nakano, T.; Uebayasi, M. Fragment molecular orbital method: an  
470 approximate computational method for large molecules. *Chemical Physics Letters* **1999**, *313*, 701 – 706.  
471 doi:10.1016/S0009-2614(99)00874-X.
- 472 45. Hevener, K.E.; Pesavento, R.; Ren, J.; Lee, H.; Ratia, K.; Johnson, M.E. Chapter Twelve - Hit-to-Lead: Hit  
473 Validation and Assessment. In *Modern Approaches in Drug Discovery*; Lesburg, C.A., Ed.; Academic Press,  
474 2018; Vol. 610, *Methods in Enzymology*, pp. 265 – 309. doi:https://doi.org/10.1016/bs.mie.2018.09.022.
- 475 46. Sterling, T.; Irwin, J.J. ZINC 15 – Ligand Discovery for Everyone. *Journal of Chemical Information and*  
476 *Modeling* **2015**, *55*, 2324–2337. doi:10.1021/acs.jcim.5b00559.
- 477 47. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM—A new method for protein modeling and design: Applications  
478 to docking and structure prediction from the distorted native conformation. *Journal of Computational*  
479 *Chemistry* **1994**, *15*, 488–506. doi:10.1002/jcc.540150503.
- 480 48. Abagyan, R.; Totrov, M. Biased Probability Monte Carlo Conformational Searches and Electrostatic  
481 Calculations for Peptides and Proteins. *Journal of Molecular Biology* **1994**, *235*, 983 – 1002.  
482 doi:10.1006/jmbi.1994.1052.
- 483 49. Totrov, M.; Abagyan, R. Rapid boundary element solvation electrostatics calculations in folding  
484 simulations: Successful folding of a 23-residue peptide. *Peptide Science* **2001**, *60*, 124–133.  
485 doi:10.1002/1097-0282(2001)60:2<124::AID-BIP1008>3.0.CO;2-S.
- 486 50. An, J.; Totrov, M.; Abagyan, R. Pocketome via Comprehensive Identification and Classification of Ligand  
487 Binding Envelopes. *Molecular & Cellular Proteomics* **2005**, *4*, 752–761. doi:10.1074/mcp.M400159-MCP200.
- 488 51. Fernandez-Recio, J.; Totrov, M.; Skorodumov, C.; Abagyan, R. Optimal docking area: A new method  
489 for predicting protein–protein interaction sites. *Proteins: Structure, Function, and Bioinformatics* **2005**,  
490 *58*, 134–143. doi:10.1002/prot.20285.

- 491 52. Fernandez-Recio, J.; Totrov, M.; Abagyan, R. ICM-DISCO docking by global energy optimization  
492 with fully flexible side-chains. *Proteins: Structure, Function, and Bioinformatics* **2003**, *52*, 113–117.  
493 doi:10.1002/prot.10383.
- 494 53. Méndez, R.; Leplae, R.; Lensink, M.F.; Wodak, S.J. Assessment of CAPRI predictions in rounds 3–5  
495 shows progress in docking procedures. *Proteins: Structure, Function, and Bioinformatics* **2005**, *60*, 150–169.  
496 doi:10.1002/prot.20551.
- 497 54. Méndez, R.; Leplae, R.; De Maria, L.; Wodak, S.J. Assessment of blind predictions of protein–protein  
498 interactions: Current status of docking methods. *Proteins: Structure, Function, and Bioinformatics* **2003**,  
499 *52*, 51–67. doi:10.1002/prot.10393.
- 500 55. Frisch, M.; Trucks, G.; Schlegel, H.; Scuseria, G.; Robb, M.; Cheeseman, J.; Scalmani, G.; Barone, V.;  
501 Mennucci, B.; Petersson, G.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H.; Izmaylov, A.; Bloino, J.;  
502 Zheng, G.; Sonnenberg, J.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima,  
503 T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, Jr., J.; Peralta, J.; Ogliaro, F.; Bearpark, M.; Heyd,  
504 J.; Brothers, E.; Kudin, K.; Staroverov, V.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant,  
505 J.; Iyengar, S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J.; Klene, M.; Knox, J.; Cross, J.; Bakken, V.; Adamo,  
506 C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.; Yazyev, O.; Austin, A.; Cammi, R.; Pomelli, C.; Ochterski, J.;  
507 Martin, R.; Morokuma, K.; Zakrzewski, V.; Voth, G.; Salvador, P.; Dannenberg, J.; Dapprich, S.; Daniels, A.;  
508 Farkas, O.; Foresman, J.; Ortiz, J.; Cioslowski, J.; Fox, D. *Gaussian 09*; Gaussian, Inc: Wallingford, CT, 2009.
- 509 56. Case, D.; Ben-Shalom, I.; Brozell, S.; Cerutti, D.; Cheatham, III, T.; Cruzeiro, V.; Darden, T.; Duke, R.;  
510 Ghoreishi, D.; Gilson, M.; Gohlke, H.; Goetz, A.; Greene, D.; Harris, R.; Homeyer, N.; Izadi, S.; Kovalenko,  
511 A.; Kurtzman, T.; Lee, T.; LeGrand, S.; Li, P.; Lin, C.; Liu, J.; Luchko, T.; Luo, R.; Mermelstein, D.; Merz, K.;  
512 Miao, Y.; Monard, G.; Nguyen, C.; Nguyen, H.; Omelyan, I.; Onufriev, A.; Pan, F.; Qi, R.; Roe, D.; Roitberg,  
513 A.; Sagui, C.; Schott-Verdugo, S.; Shen, J.; Simmerling, C.; Smith, J.; Salomon-Ferrer, R.; Swails, J.; Walker,  
514 R.; Wang, J.; Wei, H.; Wolf, R.; Wu, X.; Xiao, L.; York, D.; Kollman, P. *AMBER 2018*; University of California:  
515 San Francisco, CA, 2018.
- 516 57. Su, P.C.; Tsai, C.C.; Mehboob, S.; Hevener, K.E.; Johnson, M.E. Comparison of radii sets, entropy,  
517 QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies  
518 of *F. tularensis* enoyl-ACP reductase (FabI). *Journal of Computational Chemistry* **2015**, *36*, 1859–1873.  
519 doi:10.1002/jcc.24011.
- 520 58. Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff 14SB: Improving  
521 the Accuracy of Protein Side Chain and Backbone Parameters from ff 99SB. *Journal of chemical theory and  
522 computation* **2015**, *18*, 3696–3713. doi:10.1021/acs.jctc.5b00255.
- 523 59. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general  
524 Amber force field. *Journal of Computational Chemistry* **2004**, *25*, 1157–1174. doi:10.1002/jcc.20035.
- 525 60. Onufriev, A.V.; Izadi, S. Water models for biomolecular simulations. *WIREs Computational Molecular Science*  
526 **2018**, *8*, e1347. doi:10.1002/wcms.1347.
- 527 61. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple  
528 potential functions for simulating liquid water. *The Journal of Chemical Physics* **1983**, *79*, 926–935.  
529 doi:10.1063/1.445869.
- 530 62. Miller, B.R.; McGee, T.D.; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA.py: An efficient  
531 program for end-state free energy calculations. *Journal of Chemical Theory and Computation* **2012**, *8*, 3314–3321.  
532 doi:10.1021/ct300418h.
- 533 63. Ben-Shalom, I.Y.; Pfeiffer-Marek, S.; Baringhaus, K.H.; Gohlke, H. Efficient Approximation of Ligand  
534 Rotational and Translational Entropy Changes upon Binding for Use in MM-PBSA Calculations. *Journal of  
535 Chemical Information and Modeling* **2017**, *57*, 170–189. doi:10.1021/acs.jcim.6b00373.
- 536 64. Genheden, S.; Ryde, U. Comparison of the Efficiency of the LIE and MM/GBSA Methods to  
537 Calculate Ligand-Binding Energies. *Journal of Chemical Theory and Computation* **2011**, *7*, 3768–3778.  
538 doi:10.1021/ct200163c.
- 539 65. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods.  
540 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. *Journal of  
541 chemical information and modeling* **2011**, *51*, 69–82. doi:10.1021/ci100275a.

Version September 2, 2020 submitted to *Molecules*

22 of 22

542 © 2020 by the authors. Submitted to *Molecules* for possible open access publication under the terms and conditions  
543 of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).